Rusan Pharma: Rusan Pharma opens new API facility in Pithampur with Rs 300 crore investment

Share this post on:

Rusan Pharma, the Mumbai-based drug maker that specialises in de-addiction and pain management products, said it has launched a new active pharmaceutical ingredient (API) facility in Pithampur, Special Economic Zone (SEZ), Madhya Pradesh.

Rusan said the total investment over two phases on setting up of the factory will be upto Rs 300 crores.

With the production capability of 400 metric tonnes of APIs annually, the facility significantly contributes to Rusan Pharma’s growth and expansion plans, diversifying its portfolio and expanding its reach in India and other markets.

Once it is fully operational, the facility will directly generate more than 300 employment opportunities, and over the years, more than 500 indirect employment opportunities will be created.

“With an investment of about Rs. 300 crore in two phases, this new API facility will increase our current API manufacturing capacity from 40 metric tonnes in Ankleshwar to 400 metric tonnes in Pithampur,” said Dr. Kunal Saxena, MD of Rusan Pharma.

“Our new plant boasts five modular API manufacturing blocks with dedicated suites for finished API manufacturing. This grants us complete control over the quality of our products and reduces our dependency on imports,” Saxena said.Rusan is the leading manufacturer of highly regulated controlled substances that are used for treatment of pain, drug, alcohol, and tobacco addiction. The company, through its research and development (R&D), has developed complex formulations like sublingual tablets and transdermal patches, that are abuse free.It was the first company to introduce ‘Buprenorphine Sublingual and Buprenorphine Naloxone Sublingual Tablets’ for the treatment of drug abuse in India.

Previously, the company had launched Apomorphine Injections for treating Parkinson’s. It also specialises in the category of transdermal patches and was the first company to launch indigenous formulations of Fentanyl, Buprenorphine, and Lidocaine transdermal patches for moderate to chronic pain and Nicotine transdermal patches for tobacco cessation.

Rusan said its current good manufacturing practices (GMP) approvals for its APIs and finished formulations facilities have the potential to cater to 90% of the world’s demand.

Some of the GMP approvals they are accredited with are Health Canada, TGA-Australia, SAPHRA-South Africa, EU, UAE, and Russia, among others.

Share this post on:

Leave a Reply

Your email address will not be published. Required fields are marked *